<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Zepbound on GLP-1 Guide — Ozempic, Wegovy, Mounjaro</title><link>https://glp1decode.com/tags/zepbound/</link><description>Recent content in Zepbound on GLP-1 Guide — Ozempic, Wegovy, Mounjaro</description><image><title>GLP-1 Guide — Ozempic, Wegovy, Mounjaro</title><url>https://glp1decode.com/images/default-og.png</url><link>https://glp1decode.com/images/default-og.png</link></image><generator>Hugo</generator><language>en</language><lastBuildDate>Sat, 04 Jul 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://glp1decode.com/tags/zepbound/index.xml" rel="self" type="application/rss+xml"/><item><title>Zepbound for weight loss: what the clinical trials actually show</title><link>https://glp1decode.com/posts/zepbound-tirzepatide-weight-loss-2026/</link><pubDate>Sat, 04 Jul 2026 00:00:00 +0000</pubDate><guid>https://glp1decode.com/posts/zepbound-tirzepatide-weight-loss-2026/</guid><description>Zepbound (tirzepatide) is the newest GLP-1/GIP dual agonist approved for weight loss. We break down the SURMOUNT trial results, real-world outcomes, side effects, and how it compares to Wegovy and Mounjaro.</description></item></channel></rss>